Veloxis Pharmaceuticals A/S (CPH:VELO), a commercial-stage, specialty pharmaceutical company committed to improving the lives of transplant patients, on Tuesday reported net income of USD7.7m for the first nine months of 2019.
This was an improvement over a net loss of USD4.1m in the corresponding nine months of 2018.
Product revenues for the first nine months of 2019 were USD54.5m, up by 97% as compared with the corresponding nine months of the year before.
US revenues for the period increased by 98% to USD 47.3m, while EU revenues increased by 80% to USD7.0m, as compared to the corresponding periods of 2018, respectively.
Also, over 96% of US transplant centers have used Envarsus since its launch.
In addition, on 31 October 2019, Veloxis revised its 2019 outlook of revenues to be in the range of USD75m to USD82m and operating income, before accounting for stock compensation, to be in the range of USD15m to USD22m.
This compares with the prior outlook of revenues to be USD69m to USD77m and operating income, before accounting for stock compensation, to be in the range of USD10m to USD15m.
Quest Diagnostics announces quarterly cash dividend
Moberg Pharma posts profit of SEK32.7m in Q1 2019
RaySearch announces EUR1.5m order for RayStation from SPHIC in Shanghai
Sinovac Biotech Ltd posts net income of USD6.3m for Q3 2019
Titan Pharmaceuticals announces Q3 2019 financial results
Veloxis Pharmaceuticals swings to profit in first nine months of 2019
Mesa Labs closes acquisition of Gyros Protein Technologies for cash consideration of USD180m
UnitedHealth Group to pay dividend to holders of record as of 9 December 2019